September 22, 2022
The U.S. solicitor general says that the U.S. Supreme Court should not consider Amgen's appeal of a Federal Circuit decision tossing its jury win against Sanofi and Regeneron Pharmaceuticals Inc. over two antibody patents on its cholesterol medication Repatha.
July 15, 2022
The U.S. Supreme Court will consider several appeals from drugmakers seeking clarity on what constitutes an adequate written description for a patent, and a high-profile dispute over so-called "skinny labels" for generic drugs. Here are the cases to keep an eye on for the rest of the year.
April 18, 2022
The U.S. Supreme Court asked the solicitor general Monday to weigh in on Amgen's bid to undo a Federal Circuit decision tossing its jury win against Sanofi and Regeneron Pharmaceuticals Inc. after finding two antibody patents on its cholesterol medication Repatha aren't enabled.
March 14, 2022
Sanofi and Regeneron on Monday urged the U.S. Supreme Court to turn away Amgen's petition regarding when antibody-based patents are enabled, saying Amgen's bid to overly expand its patent rights over a certain class of cholesterol drugs was a rightfully rejected "gambit."
January 03, 2022
The U.S. Supreme Court may consider whether a car part is a law of nature that can't be patented, and multiple courts are mulling the extent of the Patent Trial and Appeal Board's discretionary powers. Here's what you need to know about these and other high-profile patent cases.
December 22, 2021
GlaxoSmithKline and a group of law professors urged the U.S. Supreme Court on Wednesday to throw out a Federal Circuit decision invalidating two Amgen cholesterol drug patents, saying it set patent validity rules that are "impossible" for many life sciences patents to meet.
November 23, 2021
Amgen Inc. has asked the U.S. Supreme Court to overrule the Federal Circuit's invalidation of two patents covering its cholesterol medication Repatha, saying the circuit court's ruling "invades" the role of a jury and misunderstands enablement standards.